PAUL GOLDENHEIM

Chairman
pulmonary
RSPR
Sweden

Business Expert Pulmonology
Biography

 Paul Goldenheim joined the RSPR Pharma Board of Directors as Chairman in September 2014. He is trained as a pulmonary physician and is currently working as a director and consultant in the field of biotechnology, serving on the Boards of Directors of several companies including Adenium, and Hydra Biosciences. Paul has a long history in pharmaceutical research, development, and management, most recently as President of TransForm Pharmaceuticals (acquired by Johnson & Johnson) and Vice-Chairman of the Board of Directors of Hypnion (acquired by Eli Lilly). Paul also serves on the board of directors of The Big Apple Circus. Dr. Goldenheim has authored numerous scientific publications and been an inventor on a number of pharmaceutical patents. He received his AB from Harvard College magna cum laude with highest honors in biochemical sciences and his MD from Harvard Medical School.

Research Intrest

 pulmonary